Liberia

The U.S. President’s Emergency Plan for AIDS Relief has delivered remarkable lifesaving results, with several countries approaching UNAIDS 95-95-95 goals for HIV epidemic control.  As countries like Liberia come closer to their targets, challenges to close the remaining gaps and cross the “last mile” become more difficult, requiring innovative, targeted approaches to ensure equity and extend services to the hardest-to reach populations and underserved areas. Global Reach II is a five-year project that supports the delivery of effective solutions to address these challenges in country-level HIV responses, adapting to the country contexts. Funded through the U.S. Health Resources and Services Administration (HRSA), Jhpiego leads the project with the following partners: University of California San Francisco, International Treatment Preparedness Coalition, Project ECHO, African Forum for Research and Education in Health (AFREhealth), Johns Hopkins University Center for Global Health and Ata Health Strategies.

With funding from Gavi, the Vaccine Alliance, Jhpiego is providing technical assistance to the Ministry of Health to facilitate their efforts to plan for, introduce and scale up their malaria vaccine program through 2025, including an effective, phased introduction of the malaria vaccine that incorporates principles of equity to reach prioritized locations and groups. The program seeks to: 1) integrate the vaccine services with existing immunization, malaria and primary health care programs; 2) reinforce linkages between existing malaria and immunization programs; 3) prioritize reaching those most at need with effective multi-dose malaria vaccination; 4) integrate approaches to supervision, information systems, program monitoring and learning that adapt and improve country capacity to track and advocate for progress; 5) use implementation science to inform local and global practice and bodies of evidence; and 6) address gender-related barriers to vaccine uptake and service quality.